MedTrace Logo

SYS6090 Combination Therapy in Advanced Lung Cancer

NCT07472647 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 596

Last updated 2026-03-16

No results posted yet for this study

Summary

This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.

Conditions

Interventions

DRUG

SYS6090 + pemetrexed + platinum-based chemotherapy

In this group, participants will receive SYS6090 in combination with pemetrexed and platinum-based chemotherapy.

DRUG

SYS6090 + paclitaxel + platinum-based chemotherapy

In this group, participants will receive SYS6090 in combination with paclitaxel and platinum-based chemotherapy.

DRUG

SYS6090 + docetaxel

In this group, participants will receive SYS6090 in combination with docetaxel.

DRUG

SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy

In this group, participants will receive SYS6090 in combination with pemetrexed, bevacizumab, and platinum-based chemotherapy

DRUG

SYS6090 + SYS6010

In this group, participants will receive SYS6090 and SYS6010.

DRUG

SYS6090 + etoposide + platinum-based chemotherapy

In this group, participants will receive SYS6090 in combination with etoposide and platinum-based chemotherapy.

DRUG

SYS6090 + chemotherapy or other anticancer therapy

In this group, participants will receive SYS6090 in combination with chemotherapy or other anticancer therapies.

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2029-02-28
Completion
2030-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07472647 on ClinicalTrials.gov